AI Insight
This phase 3 randomized controlled trial evaluated a fixed-duration combination therapy of pirtobrutinib plus venetoclax-rituximab (PVR) compared to venetoclax-rituximab (VR) alone in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma. The PVR regimen demonstrated significant improvement in progression-free survival compared to VR, with consistent benefits observed in patients who had previously received covalent BTK inhibitors and no new safety concerns identified. This represents the first randomized phase 3 evidence comparing a novel fixed-duration regimen to the current standard VR therapy in this patient population.
Why it matters
This trial establishes PVR as a potential new standard of care for patients with relapsed or refractory chronic lymphocytic leukaemia, offering improved disease control particularly for those who have exhausted other treatment options including prior BTK inhibitor therapy. The fixed-duration approach may provide an alternative to continuous treatment regimens, potentially reducing long-term treatment burden for patients.
Understand the Science
In patients with previously treated chronic lymphocytic leukaemia, PVR showed significant improvement in progression-free survival compared with VR, with consistent results in patients who had previously received covalent BTK inhibitors and no new safety signals. To our knowledge, these results represent the first randomised phase 3 evidence comparing a novel fixed-duration regimen to the current standard of VR in relapsed or refractory chronic lymphocytic leukaemia, supporting PVR as a potential new standard of care.